Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis.
Standard
Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. / Grünewald, Anne; Breedveld, Guido J; Lohmann-Hedrich, Katja; Rohé, Christan F; König, Inke R; Hagenah, Johann; Vanacore, Nicola; Meco, Giuseppe; Antonini, Angelo; Goldwurm, Stefano; Lesage, Suzanne; Dürr, Alexandra; Binkofski, Ferdinand; Siebner, Hartwig; Münchau, Alexander; Brice, Alexis; Oostra, Ben A; Klein, Christine; Bonifati, Vincenzo.
In: NEUROGENETICS, Vol. 8, No. 2, 2, 2007, p. 103-109.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis.
AU - Grünewald, Anne
AU - Breedveld, Guido J
AU - Lohmann-Hedrich, Katja
AU - Rohé, Christan F
AU - König, Inke R
AU - Hagenah, Johann
AU - Vanacore, Nicola
AU - Meco, Giuseppe
AU - Antonini, Angelo
AU - Goldwurm, Stefano
AU - Lesage, Suzanne
AU - Dürr, Alexandra
AU - Binkofski, Ferdinand
AU - Siebner, Hartwig
AU - Münchau, Alexander
AU - Brice, Alexis
AU - Oostra, Ben A
AU - Klein, Christine
AU - Bonifati, Vincenzo
PY - 2007
Y1 - 2007
N2 - PINK1 gene mutations are a cause of recessively inherited, early-onset Parkinson's disease. In some patients, a single heterozygous mutation has been identified, including the recurrent c.1366C>T transition. The interpretation of this finding remains controversial. Furthermore, the c.1366C>T mutation is associated with lower levels of PINK1 transcript, raising the question of whether mRNA levels correlate with the clinical status. We sequenced genomic DNA and copy DNA (cDNA) from 20 subjects carrying the c.1366C>T mutation in the homozygous (n = 5) or heterozygous (n = 15) state. In 17 mutation carriers, messenger RNA (mRNA) was quantified by real-time PCR using four different assays (PINK1 exon 5-6 or exon 7-8 relative to control genes SDHA or YWHAZ). Genomic sequencing confirmed the presence and zygosity of PINK1 mutations. cDNA sequencing in heterozygous mutation carriers revealed a strong wild-type and a much weaker or almost absent mutant signal, whereas in the homozygous patients, only the mutant signal was detected. Homozygous and heterozygous carriers showed PINK1 mRNA levels relative to a reference gene in the range of 0.1-0.2 and 0.5-0.6, respectively, compared with values of 0.9-1.0 in mutation-negative individuals. Treatment of lymphoblasts from a heterozygous mutation carrier with cycloheximide markedly increased the mutant transcript signal. We conclude that the recurrent PINK1 c.1366C>T mutation exerts a major effect at the mRNA level (80-90% reduction), most likely via nonsense-mediated mRNA decay. The absence of correlation between PINK1 mRNA levels and clinical status in heterozygous mutation carriers suggests that other genetic or environmental factors play a role in determining the phenotypic variability associated with the c.1366C>T mutation.
AB - PINK1 gene mutations are a cause of recessively inherited, early-onset Parkinson's disease. In some patients, a single heterozygous mutation has been identified, including the recurrent c.1366C>T transition. The interpretation of this finding remains controversial. Furthermore, the c.1366C>T mutation is associated with lower levels of PINK1 transcript, raising the question of whether mRNA levels correlate with the clinical status. We sequenced genomic DNA and copy DNA (cDNA) from 20 subjects carrying the c.1366C>T mutation in the homozygous (n = 5) or heterozygous (n = 15) state. In 17 mutation carriers, messenger RNA (mRNA) was quantified by real-time PCR using four different assays (PINK1 exon 5-6 or exon 7-8 relative to control genes SDHA or YWHAZ). Genomic sequencing confirmed the presence and zygosity of PINK1 mutations. cDNA sequencing in heterozygous mutation carriers revealed a strong wild-type and a much weaker or almost absent mutant signal, whereas in the homozygous patients, only the mutant signal was detected. Homozygous and heterozygous carriers showed PINK1 mRNA levels relative to a reference gene in the range of 0.1-0.2 and 0.5-0.6, respectively, compared with values of 0.9-1.0 in mutation-negative individuals. Treatment of lymphoblasts from a heterozygous mutation carrier with cycloheximide markedly increased the mutant transcript signal. We conclude that the recurrent PINK1 c.1366C>T mutation exerts a major effect at the mRNA level (80-90% reduction), most likely via nonsense-mediated mRNA decay. The absence of correlation between PINK1 mRNA levels and clinical status in heterozygous mutation carriers suggests that other genetic or environmental factors play a role in determining the phenotypic variability associated with the c.1366C>T mutation.
M3 - SCORING: Zeitschriftenaufsatz
VL - 8
SP - 103
EP - 109
JO - NEUROGENETICS
JF - NEUROGENETICS
SN - 1364-6745
IS - 2
M1 - 2
ER -
